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Insulin plays an important role in regulation of lipid and glucose metabolism. Retinoic acid recep-
tor-related orphan receptor a (RORa) modulates physiopathological processes such as dyslipidemia
and diabetes. In this study, we found overexpression of RORa in INS1 cells resulted in increased
expression and secretion of insulin. Suppression of endogenous RORa caused a decrease of insulin
expression. Luciferase and electrophoretic mobility shift assay (EMSA) assays demonstrated that
RORa activated insulin transcription via direct binding to its promoter. RORa was also observed
to regulate BETA2 expression, which is one of the insulin active transfactors. In vivo analyses
showed that the insulin transcription is increased by the synthetic RORa agonist SR1078. These ﬁnd-
ings identify RORa as a transcriptional activator of insulin and suggest novel therapeutic opportu-
nities for management of the disease.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Insulin is a peptide hormone, produced by beta cells of the pan-
creas and plays an important role in regulation of lipid metabolism
and glucose metabolism [1,2]. The variation of insulin level can in-
duce many metabolism diseases, such as obesity and dyslipidemia,
especially diabetes [3]. Therefore, identiﬁcation and characteriza-
tion of the factors regulating insulin transcription and secretion
will provide insights into the pathogenesis of these diseases. The
expression of the insulin gene in pancreatic beta cell is regulated
by combination of transcription factors [4], such as PDX1 [5], MAFA
[6,7], BETA2 [8].
Nuclear hormone receptors (NHRs) function as ligand-depen-
dent DNA binding factors that translate hormonal, nutritional
and pathophysiological signals into gene regulation [9–11]. In the
context of metabolism, NHRs control lipid and glucose homeostasis
in an organ- or tissue-speciﬁc manner [12]. Dysfunctional NHR sig-
nalling has been associated with dyslipidaemia, insulin resistance,
diabetes and obesity [13–15]. Hence NHR has an important role in
regulating insulin biosynthesis and is increasingly recognized as an
important target for combating type 2 diabetes [15].Retinoic acid receptor-related orphan receptor (ROR) alpha is a
member of the NHR superfamily [16]. RORa has the typical struc-
ture of a nuclear receptor including a ligand-binding domain linked
to a DNA-binding domain via a hinge region and an N-terminal re-
gion that modulates its transcriptional activity. RORa regulate
gene expression by binding as a monomer to ROR-responsive ele-
ments (ROREs) found in target gene promoters. A typical RORE is
composed of a 5-bp AT-rich sequence preceding the half-core (A/
G)GGTCA motif [16]. RORa has been identiﬁed to control the tran-
scription of the genes important in regulation of lipid and glucose
metabolism, such as genes encoding apolipoprotein A1, A5 and C3,
and glucose 6-phosphatase [17–20]. A spontaneous mutation con-
sisting of a deletion within the RORa gene that prevents transla-
tion of the RORa ligand-binding domain has been identiﬁed in
the staggerer mouse [21]. In addition to severe neurological disor-
ders, the homozygous staggerer (RORasg/sg) mice display metabolic
abnormalities. These mice have severe hypoalphalipoproteinemia
and atherosclerosis on an atherogenic diet [22,23]. Phenotypes ob-
served in RORasg/sg mice also revealed a role for RORa in modulat-
ing diet-induced obesity, insulin sensitivity and glucose uptake
[24,25]. Moreover, RORa was identiﬁed as a diabetes susceptibility
locus in Mexican Americans [26]. We recently found that the plas-
ma insulin levels were regulated by locus containing RORa on
mouse chromosome 9 [27]. However, the functional mechanism
of RORa in the regulation of insulin synthesis is remains unclear.
In the present study, we demonstrated that RORa positively and
directly regulates insulin gene expression. In addition, we have
Table 1
Sequence of primers.
Gene Primers sequence (50-30)
Forward Reverse
Ins1 AGCAAGCAGGTCATTGTTCC ACGACGGGACTTGGGTGT
Ins2 GGAGCGTGGATTCTTCTACAC TGCCAAGGTCTGAAGGTCAC
Pdx1 CCAGAGTTCAGTGCTAATCC CCCAGTCTCGGTTTCATTCG
Beta2 TCCAGGGTTATGAGATCGTCAC TTCTTGTCTGCCTCGTGTTCC
Mafa CTGCTCCTCGGTGCTCTCTT GGTTCAGGTGGTGCTGATACC
Gapdh CTCTCTGCTCCTCCCTGTTC GACTGTGCCGTTGAACTTGC
1072 J. Kuang et al. / FEBS Letters 588 (2014) 1071–1079provided evidence that RORa regulate insulin expression indirectly
by stimulating the expression of BETA2, which is one of the insulin
gene active transcription factors. Our data identify insulin as a no-
vel target gene for RORa and suggest a new role for RORa in
diabetes.
2. Materials and methods
2.1. Plasmid and virus
The rat Ins2 gene promoter (754 to +188) was ampliﬁed from
genomic DNA of INS-1 cells and cloned into pGL3-Basic reporter
vector (Promega, USA). The cDNA encoding full-length mouse
RORa was ampliﬁed by RT-PCR and then subcloned into the
pAdTrack-CMV vector through SalI and HindIII restriction sites.
Mouse RORa has 98% identity with rat RORa at the amino acid le-
vel. The resultant plasmid was then transformed into BJ5183 cells
containing the Adeasy-c1 adenoviral backbone plasmid to produce
the recombinant adenovirus plasmid, which was then transfected
into Hek293 cells by Lipofectamine™2000 (Invitrogen, USA) to al-
low packaging and ampliﬁcation of the recombinant adenovirus
(Ad-RORa). The adenovirus was puriﬁed using Adeno-x™ Virus
Mini Puriﬁcation Kit (Clontech) and the infective titer was deter-
mined by a limiting dilution plaque assay. The efﬁciency of adeno-
viral infection was examined by using the adenovirus Ad-RORa
tagged with green ﬂuorescence protein.
2.2. Overexpression and knockdown
The rat insulinoma cell line (INS-1) was cultured in RPMI-1640
(Gibco) containing 11.2 mmol/l glucose and 2 mmol/l L-glutamine
at 37 C with 5%CO2. The medium was supplemented with 10% fe-
tal bovine serum (FBS) (Hyclone), 100 unit/ml penicillin (Gibco),
100 lg/ml streptomycin (Gibco), and 50 lmol/l 2-mercaptoethaol
(Gibco). INS-1 cells were plated in 6-well plate one day before
infection. The cells were infected with adenovrius at the moi of
40 and cultured in 2% FBS medium for 4 h, and then switched to
regular growth media. 48 h later, the media were collected for ELI-
SA, and the cells were harvested for quantitative PCR or Western
blot. The water-soluble tetrazolium salt (WST-1) assay (Roche
Diagnostics, Mannheim, Germany) was performed to assess the
effects of adenovirus and adenovirus-mediated RORa overexpres-
sion on the INS-1 cell viability. For knockdown assay, INS-1 cells
were transfected with 4 lg/well control shRNA or RORa shRNA
plasmid (GenePharma, Shanghai, China) using Lipofect-
amine™2000. After 48 h, the cells were collected to perform
quantitative PCR assay or Western blot. The media were subjected
to ELISA.
2.3. RNA and protein analysis
Total RNA was extracted from INS-1 cells using Trizol reagent
(Invitrogen). We performed real-time quantitative PCR analysis as
previously described (primers in Table 1) [28].
For Western blot assay, INS-1 cells were lysed in RIPA buffer
(150 mM NaCl, 1% NP40, 0.1% SDS, 0.5% deoxycholic sodium salt,
50 mM Tris HCl, pH 7.4, 2 mM EDTA, 2 mM Na3VO4, 10 mM NaF,
one tablet of complete inhibitor cocktail (Roche Diagnostics) in
30 ml). Protein concentration was measured using a BCA protein
assay kit (Qiagen), 20 lg proteins from each sample was sepa-
rated by 10% SDS–PAGE and then transferred to a polyvinylidene
diﬂuoride membrane (Millipore) and immunoblotted with the
respective primary antibodies. Antibodies were anti-RORa anti-
body (Santa Cruz), anti-BETA2 antibody (Cell Signal technology)
and anti-b-actin (Milipore). Blots were then washed andsubsequently incubated with the secondary horseradish peroxi-
dase-conjugated antibodies (Sigma–Aldrich). Signals were re-
vealed by using an enhanced chemiluminescence kit according
to manufacturer’s instructions (Millipore).
2.4. Transient transfection and dual luciferase activity assay
INS-1 cells plated in 96-well plate were transiently transfected
with 20 ng/well of control or Ins2 promoter reporter plasmid
using Lipofectamine™2000 (Invitrogen). 12 h post-treatment, the
cells were infected with vehicle or RORa adenovirus for an addi-
tional 24 h. For RNAi assay, RORa shRNA or control shRNA was
individually, with Ins2 promoter reporter plasmid, cotransfected
into INS-1 cells. The luciferase activity was measured by using
the Dual-Glo™ luciferase assay system according to the manufac-
turer’s protocols (Promega). The ﬁreﬂy luciferase activity was nor-
malized to the Renilla luciferase activity (ﬁreﬂy luciferase/Renilla
luciferase) and presented as relative luciferase activity.
2.5. Enzyme linked immunosorbent assay (ELISA)
To examine insulin secretion, the cells were washed twice with
Krebs-Ringer–bicarbonate–HEPES (KRBH) buffer (117 mM NaCl,
4.75 mM KCl, 5 mM NaHCO3, 1.2 mM MgSO4, 1.18 mM KH2PO4,
20 mmol/l HEPES, 2.54 mM CaCl2, 5.6 mM glucose, pH 7.4). The
cells were then starved in KRBH buffer containing 5.6 mM glucose
for 30 min and subsequently incubated for 1.5 h in KRBH buffer
with 16.7 mM glucose. Insulin in the media was measured using
rat/mouse insulin ELISA kit (Millipore). To determine the cellular
insulin content, the cells were washed with phosphate-buffered
saline and lysed in ice-cold lysis buffer. After sonication and cen-
trifugation, the insulin levels in the supernatant were determined
by using ELISA assay.
2.6. Electrophoretic mobility shift assay (EMSA)
Nuclear proteins from INS-1 cells with or without RORa adeno-
virus were extracted by NE-PER nuclear and cytoplasmic extrac-
tion reagents kit (Thermo). The 50 end Biotin-labeled wild-type
probe 50-AAACAGCAAAGTCCAGGGGTCAGGG-30 or mutant probe
50-AAACAGCAAAGTCCAGGAAGGCGGG-30 (potential RORE indi-
cated in underlined) (Qiagen) was incubated with nuclear protein
in binding buffer for 20 min using a LightShift chemiluminescent
EMSA kit (Thermo). For oligonucleotide competition experiments,
unlabeled oligonucleotides were added to the reaction at 200-fold
molar excess to the labeled probes. For RORa supershift analysis,
RORa antibody (Santa Cruz, USA) was added. The DNA–protein
complexes were separated on a 5% non-denaturing poly-acrylam-
ide gel. Then the DNA–protein complexes were transferred onto
nylon membranes, and visualized by a Chemiluminescent nucleic
acid detection module (Thermo).
J. Kuang et al. / FEBS Letters 588 (2014) 1071–1079 10732.7. Animal experiments
All experiments were in compliance with the National Institute
of Health Guide for Care and Use of Laboratory Animals and the
International Association for the Study of Pain Research Guide-
lines. Animal care and experimental procedures were approved
by the Ethics Committee of Animal Experimentation of Sichuan
University. Eight-week-old male C57BL/6J mice were housed in
a temperature- and humidity-controlled room with a 12 h light/
12 h dark cycle, and were given standard chow containing 6%
fat and water ad libitum.
2.7.1. Immunoﬂuorescence staining of mouse pancreas
Mouse pancreas was dissected and ﬂash frozen in liquid nitro-
gen, and then embedded in OCT compound (Tissue-Tek). Serial
cryosections were mounted on chrome-alun-coated slides for
Immunoﬂuorescence staining. Slides were ﬁxed with 3.7% formal-
dehyde, and then blocked in phosphate-buffered saline (PBS, pH
7.4) with 6% normal donkey serum and 0.3% Triton X-100 (Sig-
ma–Aldrich). Thereafter, sections were incubated with a goat
anti-mouse insulin antibody (Santa Cruz, 1:50 dilution) or with
a rabbit anti-mouse RORa antibody (Santa Cruz, 1:100 dilution).
After washing in PBS-Tween 0.02%, sections were immunostained
with Alexa Fluor conjugated secondary antibodies (1:500, Life
technologies). The nuclei were counterstained with 40,6-diamidi-
no-2-phenylindole (DAPI) (Life technologies). Sections were
mounted with Entellan (Merck Millipore). Image analysis was
performed with a ﬂuorescence upright microscope (ZEISS Axio
Imager, Germany).
2.7.2. Determination of the effect of SR1078 on gene expression
SR1078 is a synthetic ligand that is able to function as an ROR-
speciﬁc agonist [29]. Mice were fasted for 4 h and then injected
intraperitoneally (i.p.) with SR1078 (10 mg kg1, Sigma–Aldrich)
or dimethyl sulfoxide (DMSO) (5 mice/group). 2 h after SR1078
treatment, mice were injected with glucose (2 g kg1 i.p.). The
pancreas was harvested at the 30 min time point after the glucose
injection. The tissues were mechanically disrupted and simulta-
neously homogenized in the presence of Trizol reagent (Invitro-
gen) for RNA preparation or RIPA buffer for protein extraction.
RNA concentrations were measured with the NanoDrop ND-100
Spectrophotometer (NanoDrop Technologies, Wilmington, DE),
while RNA quality was assessed by agarose gel electorphoresis
(Fig. S1). Protein concentration was measured using a BCA protein
assay kit (Qiagen). The expressions of RORa, Ins1, Ins2 and BETA2
were assessed by quantitative PCR assay or Western blot.
2.7.3. Intraperitoneal glucose tests
For glucose tolerance test, mice were fasted for 4 h and then
treated with the RORa agonist SR1078 (10 mg kg1 i.p.) or DMSO
(5 mice/group). 2 h after treating with the compound SR1078,
mice were injected with glucose (2 g kg1 i.p.). Blood was col-
lected for glucose determination from the tip of the tail at 0, 15,
30, 60, and 120 min after the glucose injection.
2.8. Statistical analysis
All data were shown as mean ± S.D with at least three indepen-
dent experiments. The trapezoidal rule was used to determine the
area under the curve (AUC). Statistical analysis was performed
using GraphPad Prism and Student’s t, P < 0.05 was considered
statistically signiﬁcant.3. Results
3.1. RORa over-expression increases insulin expression and secretion
To identify the potential role of RORa in insulin regulation, we
over-expressed adenoviral RORa in INS-1 cells and measured the
expressions of Ins1 and Ins2 genes by real-time quantitative PCR.
As shown in Fig. 1A, the RORa overexpression signiﬁcantly in-
creased the expression of Ins2 gene but not Ins1 gene compared
with control adenovirus. Furthermore, we examined whether
RORa overexpression would result in an alteration of cellular insu-
lin content and insulin secretion. INS-1 cells were infected with
RORa adenovirus or control virus, and after 48 h the amount of
insulin in both cell and medium were measured using an ELISA.
Overexpression of RORa led to a 1.4-fold increase in cellular insulin
(Fig. 1B) and a 2.2-fold increase in secreted insulin (Fig. 1C) com-
pared with the control virus. To rule out possible effects of RORa
overexpression against apoptosis of INS-1 cells, the effect of adeno-
virus and adenoviral RORa on the viability of INS-1 cells was as-
sessed using the WST-1 assay. As shown in Fig. 1D, there was no
change in cell viability in cells transfected with adenoviral RORa
compared with the empty vector group in almost all statistical
evaluations. Collectively, these data indicate that RORa up-regu-
lates insulin gene expression.
3.2. shRNA-mediated inhibition of endogenous RORa expression
decreases insulin expression and secretion
To gain more insight into the involvement of RORa in the regu-
lation of the insulin gene, we used shRNA transfection to knock-
down endogenous RORa expression and examined its effect on
endogenous insulin mRNA expression. As depicted in Fig. 2A, Wes-
tern blot analysis conﬁrmed that the RORa shRNA signiﬁcantly de-
creased RORa protein expression. Furthermore, Fig. 2B
demonstrated that the silence of RORa led to signiﬁcant decrease
in both Ins1 and Ins2 genes expression compared to the control
shRNA as measured by quantitative PCR. In addition, we measured
the amount of insulin in both cell and medium using an ELISA. A
loss of RORa expression led to a 15.8% decrease in cellular insulin
(Fig. 2C) and a 26.7% decrease in secreted insulin (Fig. 2D) as com-
pared with the control shRNA. Taken together, these data conﬁrm
that RORa plays a key role in the physiological control of insulin
gene expression in pancreatic beta cells.
3.3. RORa enhances the activity of Ins2 gene promoter by binding
to RORE consensus
Data from overexpression and knockdown of RORa in INS-1
cells indicate that RORa regulates insulin expression. Next, we
determined whether RORa can modulate Ins2 gene promoter tran-
scriptional activity. Rat INS-1 cells were transiently co-transfected
with a luciferase reporter vector driven by the rat Ins2 promoter
fragment (754 bp to +188 bp) and the adenoviral RORa. The re-
sults in Fig. 3A shows that RORa can induce a markedly higher
Ins2 promoter activity. Inclusion of RORa resulted in an approxi-
mate 3-fold increase in Ins2 promoter-driven transcription. Then,
we showed that the transcriptional activity of the Ins2 reporter
construct was strongly increased in a dose-dependent manner by
the cotransfection of RORa expression vector in rat INS-1 cells
(Fig. 3B). This indicates that RORa regulates Ins2 positively. To con-
ﬁrm the role of RORa in the regulation of Ins2 promoter activity,
we used shRNA transfection to knock down endogenous RORa
Fig. 1. Adenovirus-mediated RORa overexpression increases insulin expression and secretion. INS-1 cells were treated with control adenovirus or RORa adenovirus at
multiplicity of infection of 40 MOI/cell for 48 h. (A) RORa overexpression in INS-1 cells increases Ins2 gene expression but no inﬂuence on Ins1 at the mRNA level as measured
by quantitative PCR. The expression in controls (AdLacZ) was normalized to a value of 1.0. (B) Cellular contented insulin and (C) secreted insulin measured by ELISA. (D) Effect
of adenoviral RORa on the viability of INS-1 cells was assessed by WST-1 assay. Values were presented as the means ± S.D. and representative of three separate experiments.
⁄, indicated P < 0.05 relative to control adenovirus.
Fig. 2. Silence of RORA by shRNA results in decreased insulin expression and secretion. INS-1 cells were treated with control shRNA or RORa shRNA for 48 h. (A) Knockdown
of RORa expression was conﬁrmed byWestern blot. b-actin was used as a loading control. (B) Decreased RORa expression in INS-1 cells leads to decreased expression of both
Ins1 and Ins2 genes as measured by quantitative PCR. The control shRNA was normalized to a value of 1.0. Decreased RORa expression leads to both the cellular contented
insulin (C) and secreted insulin (D) decreased as measured by ELISA. Values were presented as the means ± S.D. and representative of three separate experiments. ⁄, indicated
P < 0.05 relative to control shRNA.
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Fig. 3. RORa activates Ins2 gene promoter activity by binding to the RORE consensus. (A) INS-1 cells were transfected with control or RORa adenovirus along with the Ins2
reporter construct. The overexpression of RORa dramatically increases Ins2 promoter activity. (B) RORa increases Ins2 gene promoter activity in a dose-dependent manner.
Luciferase values were normalized using Renilla luciferase. (C) INS-1 cells were transfected with control shRNA or RORa shRNA along with the Ins2 reporter construct.
Knockdown of RORa expression reduces Ins2 gene promoter activity. (D) Schematic of the Ins2 promoter. Sequence analysis revealed the presence of two putative RORE
located at nucleotides 54 bp and +162 bp from the transcription start site, respectively. (E) The RORE at nucleotide 54 bp is evolutionary conserved among rat, human and
chimpanzee. (F) Using an EMSA assay, it is determined that RORa binding to the Ins2 RORE is speciﬁc and competitive. The labeled wild-type probe was incubated with
control buffer without nuclear proteins (lane1). The labeled wild-type probe (lane 2) or labeled mutant-type probe (lane 3) was incubated with nuclear proteins in the
absence of competitor. For competition, unlabelled oligonucleotide containing the consensus RORE (cold probe) was added at 200-fold excess (lane 4). Supershift assays with
biotin labeled probe and nuclear extracts in the presence of anti-RORa antibody (lane 5). Values (a–c) are mean ± S.D. and representative of three separate experiments;
⁄P < 0.05 compared with corresponding controls.
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luciferase activity in the presence of RORa shRNA compared to
the control shRNA was observed. These data further suggest that
RORa may up-regulate Ins2 promoter activity by binding its
promoter.
It has been identiﬁed that RORa regulates genes expression by
binding a promoter special site which display characteristics of a
classical RORE consensus containing an (A/G)GGTCA sequence.
We searched for putative ROREs within the 2 kb of the Ins2 pro-
moter and found two putative ROREs at nucleotides 54 bp and
+162 bp from the transcription start site, respectively (Fig. 3D),
the 54 bp site is conserved in human, rat, and chimpanzee
(Fig. 3E). To conﬁrm the physical interaction of RORa with the
putative RORE sequences in Ins2 promoter, we performed the elec-
trophoretic mobility shift assay (EMSA). Biotinylated double-
strand oligonucleotide containing the Ins2 RORE (71 to 47)
was used as probe. A binding complex was formed between RORa
and the labeled wild-type Ins2 RORE (Fig. 3F, lane 2). However, the
binding was not observed with mutated probe (Fig. 3F, lane 3).
Similarly, RORa binding was completely abolished by the compet-
itive unlabeled oligonucleotides corresponding to Ins2 RORE (cold
probe) (Fig. 3F, lane 4). Furthermore, RORa was also identiﬁed in
the RORE/RORa complex by supershift analysis using anti-RORa
antibody (Fig. 3F, lane 5). Collectively, these data indicate that
RORa speciﬁcally binds to the RORE site presents between 71
and 47 bp in Ins2 gene promoter.3.4. RORa stimulates transcription factor BETA2 expression
PDX1, MAFA and BETA2 are major transcription factors in beta
cell, they directly regulate insulin gene expression [6,7,30]. There-
fore, we examined whether RORa regulated insulin expression by
modulating the expression of these insulin transactivators. Quanti-
tative PCR showed that the mRNA expression of Beta2 was signif-
icantly up-regulated while Pdx1 and Mafa have no variation in
RORa overexpressing cells as compared to Lac-expressing control
cells (Fig. 4A). Western blot analysis conﬁrmed that RORa overex-
pression signiﬁcantly enhanced BETA2 protein expression (Fig. 4B).
When we knocked down the endogenous RORa expression with
shRNA in rat INS-1 cells, BETA2 in both message and protein levels
were signiﬁcantly decreased whereas PDX1 and MAFA were not af-
fected (Fig. 4C and D). These data suggest that RORa also has an
indirect role in the regulation of the insulin promoter through its
effect on the trans-activator BETA2.
3.5. RORa induces insulin expression and secretion in vivo
We ﬁrst investigated the subtissular distribution of RORa in
mouse pancreas. Immunoﬂuorescence detection of RORa in this
tissue demonstrated a localization in b-cells as shown by insulin
costaining (Fig. 5A). To better understand the in vivo functions of
RORa in the regulation of insulin expression, mice were treated
with a synthetic RORa agonist SR1078 (10 mg kg1 i.p.), and 2 h
Fig. 4. RORa regulates insulin transcription factors expression. INS-1 cells were treated with adenovirus or shRNA for 48 h. (A) and (C) Pdx1, Mafa and Beta2 mRNA levels
were measured by quantitative PCR relative to the control. (B) and (D) The protein level of BETA2 regulated by RORa was measured by Western blot. b-Actin was used as a
loading control. The level for control was normalized to a value of 1.0. Data in the bar graph were the means ± S.D. of three separate measurements and ⁄P < 0.05 relative to
controls.
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protein puriﬁed for assessment of RORa, Ins1, Ins2 and Beta2 gene
expression. As shown in Fig. 5B–D, pancreas mRNA and protein
levels of RORawere dramatically elevated over 2-fold in mice trea-
ted with SR1078, compared with control mice. Commensurate
with the induction of RORa, the levels of Ins2 mRNA and BETA2
protein were signiﬁcantly increased versus vehicle control, which
are consistent with previous observations in INS1 cells. SR1078
also signiﬁcantly improved glucose tolerance in mice, because
the plasma glucose concentration during the glucose tolerance test
was lower at each time point in SR1078- than in vehicle-treated
animals (Fig. 5E). Accordingly, the area under the curve (AUC)
was also signiﬁcantly smaller in SR1078-treated than in vehicle-
treated mice (Fig. 5F). Together with in vitro studies, these results
conﬁrm that RORa plays a key role in the physiological control of
insulin gene expression.4. Discussion
In this study, we have established Ins2 as a novel RORa target
gene. Endogenous Ins2 mRNA expression was up-regulated by
overexpression of RORa in rat INS-1 cells. Knock-down of RORa
by shRNA produced a decrease in Ins2 mRNA. Furthermore, the al-
tered expression of RORa also led to the alteration of secreted insu-
lin and cellular content insulin accordingly. Moreover, the Ins2
promoter-driven luciferase activity was upregulated by RORa
expression. As expected, a potential RORa response element
(RORE) was found to be located in Ins2 promoter. EMSA provedthat RORa has DNA-binding ability to Ins2 promoter. In addition,
our in vivo experiment also showed that RORa activation increases
insulin production. Taken together, our study identiﬁes a new sig-
naling pathway regulating insulin expression.
Manipulation of RORa levels through stable over-expression or
shRNA knock-down also affected the level of transcription factor
BETA2 in beta cells. BETA2 is a crucial factor for the assembly
and function of the insulin gene transcription complex. This leads
us to conclude that RORa modulates insulin gene expression, both
directly through binding to the insulin promoter and indirectly by
modulating the activity of other beta-cell-enriched transcription
factors. The mRNA expression of Beta2 was up-regulated in RORa
over-expressed cells, and down-regulated in RORa-knockdown
cells, suggesting that Beta2 could be a RORa target gene. We fur-
ther analyzed Beta2 promoter for the presence of putative ROREs
and found ﬁve putative ROREs (Fig. S2), however, only the site at
2661 bp is conserved among human, mouse, and chimpanzee.
Whether RORa binds speciﬁcally to the RORE in the 50 regulatory
region of Beta2 gene will require further investigation.
Rat islets of Langerhans contain two insulins (Ins1 and Ins2)
that are products of non-allelic genes [31]. Our study showed that
over-expression of RORa led to a markedly increase of Ins2 expres-
sion but had no inﬂuence on Ins1 in INS-1 cells. However, both Ins1
and Ins2 were down-regulated when endogenous RORa gene was
knocked down by shRNA, suggesting that it is involved directly or
indirectly in the regulation of both genes. Our data demonstrated
that RORa is able to directly bind the RORE sequence of Ins2 pro-
moter, so it likely has a direct effect. The lack of response of Ins1
to RORa over-expression may indicate that its expression levels
Fig. 5. RORa agonist SR1078 elevates the expressions of Ins2 and BETA2 in vivo. Mice were treated with a synthetic RORa agonist SR1078 (10 mg kg1 i.p.) or DMSO for 2 h,
and then were injected with glucose (2 g kg1 i.p.). Thereafter, the mice were divided 2 groups. In one group, at the 30 min time point after glucose injection, the pancreas was
harvested and mRNA and protein puriﬁed for assessment of gene expression. In another group, blood was collected for glucose determination from the tip of the tail at 0, 15,
30, 60, and 120 min after the glucose injection. (A) RORa is expressed in mouse pancreatic b-cells. Insulin (red) and RORa (green) were detected by indirect
immunoﬂuorescence. Nuclei were stained with 40 ,6-diamidino-2-phenylindole (DAPI). Scale bars represent 20 lm. (B) RORa, Ins1 and Ins2 mRNA levels were measured by
quantitative PCR relative to the control. (C) and (D) The protein levels of RORa and BETA2 were measured by Western blot. b-actin was used as a loading control. The level for
control was normalized to a value of 1.0. (E) Intraperitoneal glucose tolerance test in SR1078-treated and vehicle-treated mice. (F) Area under the curve for glucose (AUC
glucose) was calculated using the trapezoidal rule. The data were presented as the means ± S.D. of ﬁve mice. ⁄P < 0.05 relative to controls.
J. Kuang et al. / FEBS Letters 588 (2014) 1071–1079 1077are near or at maximum in INS-1 cells and an increase in RORa
cannot further enhance Ins1 expression. We cannot identify a
RORE sequence in Ins1 promoter region. However, RORa can in-
crease Beta2 message and protein levels and as it is known that
BETA2 is capable of activating Ins1 promoter, we speculate that
RORa has effects on other b-cell transcription factors which may
in turn inﬂuence Ins1 expression.
RORa was initially described as an orphan nuclear receptor and
has long been considered a constitutive activator of transcription
in its exogenous ligands [16]. Later, natural ligands such as melato-
nin, cholesterol and cholesterol sulfate were shown to bind and
trans-activate RORa, although there were controversies [32]. Re-
cently, the amide SR1078 has been identiﬁed as a synthetic RORa
agonist, which is expected to bind to the RORa protein and thus
alters conformation and transactivating properties. However, our
studies showed that the amount of RORamRNA increased aftermice
was treated with SR1078 (Fig. 5B). A possible explanation is that
SR1078 increases RORa expression, which subsequently regulates
insulin expression. Actually, many RORa natural agonists, such as
melatonin and cholesterol sulfate, are known to modulate the
activity of RORa by up-regulation of RORa transcription [33,34].RORa plays an essential role in regulation of the mammalian
clock that in turn coordinates various physiological processes
[35–37]. Studies have suggested that the expressions of both RORa
and insulin are regulated in a circadian manner [38–41], leading to
the possibility that RORa may be contributing to its circadian pat-
tern of expression. We observed that RORa was highly expressed
in mouse pancreas b-cells (Fig. 5A) and rat insulinoma INS-1 cells
(Fig. 2A). This differs from those of Mühlbauer et al. who showed
RORa was preferentially located in rat a-cells [41]. The nature of
this difference is still not known. The circadian rhythm is tightly
coupled to metabolic regulation, and among several stimuli that
can entrain the clock is food [42]. This food-en-trainable oscillator
controls food-anticipatory behavior as well as other physiological
alterations in anticipation of a meal. Insulin levels are induced by
feeding, it is possible that there may also be a circadian regulatory
component to insulin secretion mediated by RORa. An aberrant
circadian rhythm can also lead to development of metabolic
syndrome. Clock mutant mice display hepatic steatosis, hyperlipid-
emia, high glucose levels, and low insulin levels [43,44]. In
humans, epidemiological data indicates that shift work is associ-
ated with increased risk for development of diabetes, obesity,
1078 J. Kuang et al. / FEBS Letters 588 (2014) 1071–1079and cardiovascular disease [45–47]. Recent studies in humans
demonstrated that controlled misalignment of the circadian
rhythm led to metabolic alterations, with some of the healthy sub-
jects exhibiting postprandial glucose responses expected of indi-
viduals in a prediabetic state [48–50].
In conclusion, we have demonstrated for the ﬁrst time that
RORa regulates insulin gene transcription by directly binding to
the insulin promoter at RORE site, which is highly conserved be-
tween rat and human. Furthermore, our data indicate that RORa
expression also may modulate insulin gene transcription by effects
on the levels of insulin transcription factor BETA2.
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